Technology
The Company has strong expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines.
A number of recombinant protein subunit vaccine candidates produced using the company’s protein production platform are currently under development. HBI also has a robust drug discovery and development program producing medical countermeasure small molecule anti-toxin drugs.
HBI also owns a semi-synthetic saponin adjuvant, GPI-0100, which elicits broad immune responses to vaccines and therapeutics, especially in the field of cancer. HBI has licensed the rights for use of the adjuvant on a non-exclusive basis to third parties, (including for use with certain animal health and cancer vaccines) and is open to additional licensing opportunities for GPI-0100.
The Company has strong expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines.
A number of recombinant protein subunit vaccine candidates produced using the company’s protein production platform are currently under development. HBI also has a robust drug discovery and development program producing medical countermeasure small molecule anti-toxin drugs.
HBI also owns a semi-synthetic saponin adjuvant, GPI-0100, which elicits broad immune responses to vaccines and therapeutics, especially in the field of cancer. HBI has licensed the rights for use of the adjuvant on a non-exclusive basis to third parties, (including for use with certain animal health and cancer vaccines) and is open to additional licensing opportunities for GPI-0100.